Target- |
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.AU |
First Approval Date04 Dec 2017 |
评价异麦芽糖酐铁1000注射液治疗慢性肾病缺铁性贫血有效性和安全性的多中心Ⅲ期临床试验
[Translation] A multicenter phase III clinical trial to evaluate the efficacy and safety of isomaltoside iron 1000 injection in the treatment of iron deficiency anemia in chronic kidney disease
评价异麦芽糖酐铁1000注射液治疗慢性肾病缺铁性贫血的有效性和安全性
[Translation] To evaluate the efficacy and safety of isomaltoside iron 1000 injection in the treatment of iron deficiency anemia in chronic kidney disease
100 Clinical Results associated with Wasserburger Arzneimittelwerk GmbH
0 Patents (Medical) associated with Wasserburger Arzneimittelwerk GmbH
100 Deals associated with Wasserburger Arzneimittelwerk GmbH
100 Translational Medicine associated with Wasserburger Arzneimittelwerk GmbH